Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Oncofertility w praktyce klin.
  • Obniżka
Designing Multi-Target Drugs

Designing Multi-Target Drugs

9781849733625
970,14 zł
873,12 zł Zniżka 97,02 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 873,12 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD.
Szczegóły produktu
Royal Society for Chemistry
77288
9781849733625
9781849733625

Opis

Rok wydania
2012
Numer wydania
1
Oprawa
twarda
Liczba stron
394
Wymiary (mm)
156.00 x 234.00
Waga (g)
713
  • Preface; Forewords; Simple drugs do not cure complex diseases - the need for multi-targeted drugs; Clinical Need and Rationale for Multi-Target Drugs in Psychiatry; Drug molecules and biology:: network and systems aspects; Chemoinformatic approaches to target identification; In vitro Panel Screening - Biological Fingerprinting; Phenotypic and in vivo Screening; Lead Discovery and Drug Repurposing; Target/s identification approaches - experimental biological approaches; Historical strategies for lead generation; In silico Lead Generation Approaches in Multi-Target Drug Discovery; The challenges of multi-target lead optimization; Combination agents versus multi-targeted agents - pros and cons; CASE STUDIES:: The Discovery of Lapatinib; Identification and optimization of dual PI3K/mTOR inhibitors; Discovery of HDAC-inhibiting multi-target inhibitors; Targeting protein-protein interactions; dual inhibitors of Bcl-2 and Bcl-xL; Discovery of the anti-psychotic drug, Ziprasidone; The Rational Design of Triple Reuptake Inhibitors for the Treatment of Depression; Discovery of multi-target agents for neurological diseases via ligand design; Designing Drugs with Dual Activity:: Novel Dual Angiotensin II and Endothelin Receptor Antagonists; Case study 10:: Ethyl Urea Inhibitors of the Bacterial Type II Topoisomerases DNA Gyrase (GyrB) and Topoisomerase IV (ParE); Epilogue; Index
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów